They build it slowly — in silence. Here’s how to stop it before it starts.
Heart Disease Doesn’t Strike Out of Nowhere
Heart attacks rarely happen out of the blue. They start decades earlier, when tiny cholesterol-carrying particles sneak into the walls of your arteries.
Your immune system spots the intruder and tries to repair the damage. The fix isn’t perfect — inflammation sets in, and over time, those damaged spots harden into plaque.
That process, called atherosclerosis, narrows arteries and cuts off oxygen to the heart. It happens quietly, without pain or warning, for years.
Many men feel perfectly fine — right up until an artery closes and the heart starves.
Emergency medicine can save lives in that moment. But many never reach the hospital. And for survivors, life changes: the heart grows weaker, fatigue sets in, and the risk of another attack remains high.
The good news? This disease is measurable, trackable, and preventable.
We can detect its early signs long before symptoms appear — if we look soon enough.
Why Most Men Don’t See It Coming
Heart disease is still the #1 cause of death for men under 65 in Europe.
Men die almost twice as often as women from it — and the gap starts young.
Even when men are told they’re high risk, half never bring blood pressure or cholesterol into a healthy range. It’s not a lack of willpower; it’s a broken system that waits until damage is already done.
Most standard checkups miss the earliest signs.
Typical cholesterol tests measure how much fat floats in the blood — not how many dangerous particles are carrying it.
That’s where ApoB comes in. ApoB is a protein tag found on every harmful lipoprotein particle. The more ApoB, the more “bullets” circulating that can damage arteries.
Men as young as their 20s often already have plaque starting to form — it just isn’t visible yet.
And there’s a genetic twist: Lp(a), a particle that never changes through life. If yours is high, your lifetime risk doubles. It’s simple to test once — but most clinics never check it.
Early testing is the difference between prevention and repair.
Why Men Are Hit Earlier — and Harder
Men face cardiovascular risk earlier than women for both biological and behavioral reasons.
From adolescence onward, men carry more ApoB particles, higher blood pressure, and more visceral fat. These all speed up the formation of arterial plaque.
Hormones also shift the odds.
Healthy testosterone helps maintain muscle, metabolism, and blood vessel function. But when it drops with age, body fat rises and metabolic health worsens — setting the stage for disease.
Add to that the cultural side: men delay checkups, downplay fatigue, and “push through.” What feels like strength is often silent damage accumulating over time.
But none of this makes heart disease inevitable. With the right information, you can reverse the odds.
The Modifiable Biology of Heart Disease
Heart disease isn’t fate. It’s measurable biology — and biology can change.
The root problem starts with too many ApoB-containing lipoproteins circulating for too long. These particles burrow into artery walls, spark inflammation, and grow plaque.
Other factors — blood pressure, glucose, insulin, and inflammation — act like accelerators on that same process.
Here’s what actually matters:
ApoB — The Root Number
ApoB tells you the number of dangerous cholesterol particles in your blood.
Fewer particles mean less plaque, steadier blood flow, and a heart that stays strong for decades.
Lp(a) — The Genetic Wildcard
Lp(a) behaves like “super sticky” LDL. It promotes clotting and plaque buildup.
It’s inherited — you only need to test once. But if it’s high, you’ll need to treat every other risk factor aggressively.
hs-CRP — The Inflammation Signal
High-sensitivity C-reactive protein (hs-CRP) shows whether your body is under silent, chronic inflammation — the same kind that destabilizes plaque and makes it rupture.
Lower inflammation, lower risk.
Insulin — The Metabolic Early Warning
Years before diabetes, rising fasting insulin signals trouble. It raises triglycerides, lowers HDL, and drives up ApoB.
Keeping insulin low through exercise, nutrition, improved muscle mass and, if needed, modern therapeutics, slows the entire disease process.
Heart disease isn’t one event. It’s a network of small, measurable changes that build over time — and every one of them can be modified.
The Cue Blueprint for a Stronger Heart
At Cue, we don’t wait for problems to appear — we prevent them.
Because heart disease isn’t a mystery. It’s measurable, and that means it’s beatable.
Because cardiovascular health is connected to everything else in the body, naturally heart health also has great importance.
Every plan, every test, every recommendation is designed to help you live longer — and better.
Your Cue Heart Health Action Plan
1. Get tested early.
Start with ApoB, Lp(a), hs-CRP, and fasting insulin. They reveal silent risk long before symptoms appear. Naturally, these are all included in the initial Cue Health Assessment [link].
2. Move more.
Strength + cardio = metabolic armor. Even 30 minutes a day changes your biology.
3. Eat for your arteries.
More plants, fiber, and healthy fats. Less processed food, sugar, and alcohol.
4. Prioritize recovery.
Sleep 7–9 hours, manage stress, and let your body repair the damage daily life creates.
5. Track and adapt.
Use wearables, blood testing, and Cue’s continuous insights to stay ahead of risk — not react to it.
Prevention isn’t passive. It’s precision.
At Cue, we help you measure what matters, act early, and keep your heart strong for life.
References
Bell, J. A., Ferreira, D. L. S., Fraser, A., Soares, A. L. G., Howe, L. D., Lawlor, D. A., Carslake, D., Smith, G. D., & O’Keeffe, L. M. (2020). Sex differences in cardiometabolic traits at four life stages: Cohort study with repeated metabolomics (p. 2020.01.15.19015206). medRxiv. https://doi.org/10.1101/2020.01.15.19015206 (https://doi.org/10.1101/2020.01.15.19015206)
Causes of death statistics—Statistics Explained—Eurostat. (n.d.). Retrieved October 27, 2025, from https://ec.europa.eu/eurostat/statistics-explained/index.php?title=Causes_of_death_statistics (https://ec.europa.eu/eurostat/statistics-explained/index.php?title=Causes_of_death_statistics)
Commentary—2019 ESC/EAS Guidelines for dyslipidaemia management. (n.d.). EAS. Retrieved October 27, 2025, from https://eas-society.org/page/commentary-2019-esc-eas-guidelines-for-dyslipidaemia-management/ (https://eas-society.org/page/commentary-2019-esc-eas-guidelines-for-dyslipidaemia-management/)
Jakab, A. E., Bukva, M., Maróti, Z., Kalmár, T., Raskó, I., Kereszty, É. M., Papp, V. Z., & Bereczki, C. (2024). The ASAP study: Association of atherosclerosis with pathobiology in a caucasian cohort—a study of 3400 autopsy reports. Scientific Reports, 14(1), 25179. https://doi.org/10.1038/s41598-024-76817-9 (https://doi.org/10.1038/s41598-024-76817-9)
Mach, F., Koskinas, K. C., Roeters van Lennep, J. E., Tokgözoğlu, L., Badimon, L., Baigent, C., Benn, M., Binder, C. J., Catapano, A. L., De Backer, G. G., Delgado, V., Fabin, N., Ference, B. A., Graham, I. M., Landmesser, U., Laufs, U., Mihaylova, B., Nordestgaard, B. G., Richter, D. J., … ESC/EAS Scientific Document Group. (2025). 2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias: Developed by the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). European Heart Journal, ehaf190. https://doi.org/10.1093/eurheartj/ehaf190 (https://doi.org/10.1093/eurheartj/ehaf190)
Mortensen, M. B. (2024). ApoB triumphs once more over LDL-C and non-HDL-C in risk prediction: Ready for guidelines? European Heart Journal, 45(27), 2419–2421. https://doi.org/10.1093/eurheartj/ehae257 (https://doi.org/10.1093/eurheartj/ehae257)
Santos, R. D. (2021). EUROASPIRE V and uncontrolled risk factors in primary prevention: Atherosclerotic cardiovascular disease in the making. European Journal of Preventive Cardiology, 28(4), 380–382. https://doi.org/10.1177/2047487320915662 (https://doi.org/10.1177/2047487320915662)
Strong, J. P., Malcom, G. T., McMahan, C. A., Tracy, R. E., Newman III, W. P., Herderick, E. E., Cornhill, J. F., & for the Pathobiological Determinants of Atherosclerosis in Youth Research Group. (1999). Prevalence and Extent of Atherosclerosis in Adolescents and Young AdultsImplications for Prevention From the Pathobiological Determinants of Atherosclerosis in Youth Study. JAMA, 281(8), 727–735. https://doi.org/10.1001/jama.281.8.727 (https://doi.org/10.1001/jama.281.8.727)
Timmis, A., Aboyans, V., Vardas, P., Townsend, N., Torbica, A., Kavousi, M., Boriani, G., Huculeci, R., Kazakiewicz, D., Scherr, D., Karagiannidis, E., Cvijic, M., Kapłon-Cieślicka, A., Ignatiuk, B., Raatikainen, P., De Smedt, D., Wood, A., Dudek, D., Van Belle, E., … ESC National Cardiac Societies. (2024). European Society of Cardiology: The 2023 Atlas of Cardiovascular Disease Statistics. European Heart Journal, 45(38), 4019–4062. https://doi.org/10.1093/eurheartj/ehae466 (https://doi.org/10.1093/eurheartj/ehae466)
